12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zysa regulatory update

Ocera said it received CE Mark approval for Zysa to treat diarrhea-predominant irritable bowel syndrome (IBS-D). The product is marketed in Asia as Kremezin...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >